Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Nanoparticle Therapies
Smart Nanoparticles May Be Able to Deliver Drugs to Heart After Heart Attack
04/18/2024

Washington University in St. Louis News

Washington University in St. Louis Ne...
With a four-year, $2.07 million grant from the NIH, researchers plan to enclose a set of proteins designed to curb inflammation and a peptide to prevent fibrosis inside cleverly disguised drug-delivering smart nanoparticles. These...
With a four-year, $2.07 million grant from the NIH, researchers plan to enclose a set of proteins designed to curb inflammation and a peptide to prevent fibrosis inside cleverly disguised drug-delivering smart nanoparticles. These...
With a four-year, $2.07 million...
04/18/2024
Cath Lab Digest
TAVR
Caranx Medical Announces Successful Robotic-Assisted Transcatheter Heart Valve Implantation in an Animal
04/17/2024

Caranx Medical News

Caranx Medical News
“The team at Caranx has achieved an important milestone as it successfully deployed a balloon-expandable device in the aortic position, in a pig model. This extremely promising step paves the way to a first-in-human utilization," says Dr....
“The team at Caranx has achieved an important milestone as it successfully deployed a balloon-expandable device in the aortic position, in a pig model. This extremely promising step paves the way to a first-in-human utilization," says Dr....
“The team at Caranx has achieved...
04/17/2024
Cath Lab Digest
Intravascular Lithotripsy
FastWave Medical Extends Intellectual Property Portfolio With the Issuance of Its Utility Patent for Novel Laser-IVL Technology
04/16/2024

FastWave Medical Inc. News

FastWave Medical Inc. News
"FastWave's novel approach has enormous potential to leapfrog today's IVL technology with durable, fast, and consistent laser energy," says Dr. William Nicholson. "It also enables FastWave's team of engineers to develop an ultra-sleek balloon...
"FastWave's novel approach has enormous potential to leapfrog today's IVL technology with durable, fast, and consistent laser energy," says Dr. William Nicholson. "It also enables FastWave's team of engineers to develop an ultra-sleek balloon...
"FastWave's novel approach has...
04/16/2024
Cath Lab Digest

Advertisement

PerQseal Elite Vascular Closure System
Venous Closure
Vivasure Medical Announces First Large Hole Venous Patient Treated With PerQseal Elite Vascular Closure System
04/15/2024

Vivasure Medical News

Vivasure Medical News
Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced it has treated the first large bore venous patient with the PerQseal® Elite vascular closure system, a sutureless and fully...
Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced it has treated the first large bore venous patient with the PerQseal® Elite vascular closure system, a sutureless and fully...
Vivasure Medical, a company...
04/15/2024
Cath Lab Digest
Wrist-based monitoring
Researchers Demonstrate the Potential for Verily's Study Watch to Help Identify Patients at Risk for Heart Failure
04/11/2024

Verily News

Verily News
A study conducted by Verily, Duke University, and Stanford University demonstrates that the walking behavior captured by Verily Study Watch, a wrist-worn device designed for research purposes, is associated with different levels of heart...
A study conducted by Verily, Duke University, and Stanford University demonstrates that the walking behavior captured by Verily Study Watch, a wrist-worn device designed for research purposes, is associated with different levels of heart...
A study conducted by Verily,...
04/11/2024
Cath Lab Digest
Tricuspid Valve Treatment
First Patient Enrolled in VISTA U.S. Study Evaluating Novel Tricuspid Valve Replacement Technology
04/11/2024

Minneapolis Heart Institute Foundation® News

Minneapolis Heart Institute Foundatio...
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollment in the VISTA U.S. early feasibility study offering a new transcatheter tricuspid valve technology for severe tricuspid valve regurgitation. Paul Sorajja, MD,...
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollment in the VISTA U.S. early feasibility study offering a new transcatheter tricuspid valve technology for severe tricuspid valve regurgitation. Paul Sorajja, MD,...
Minneapolis Heart Institute...
04/11/2024
Cath Lab Digest

Advertisement

Lower-extremity intervention
Revascularization Enhances Quality of Life for Patients With Chronic Limb-Threatening Ischemia
04/10/2024

Brigham and Women's Hospital / Boston Medical Center News

Brigham and Women's Hospital / Boston...
“Our study indicates that patients with CLTI have a notably poor quality of life – substantially lower than with many other chronic conditions,” said Matthew Menard, MD. “Our findings show that revascularization significantly improves quality...
“Our study indicates that patients with CLTI have a notably poor quality of life – substantially lower than with many other chronic conditions,” said Matthew Menard, MD. “Our findings show that revascularization significantly improves quality...
“Our study indicates that...
04/10/2024
Cath Lab Digest
Drug Safety
Acetaminophen May Be Less Heart-Safe Than Previously Thought
04/10/2024

American Physiological Society (APS) News

American Physiological Society (APS) ...
“We found that regular use of acetaminophen at concentrations that are considered safe—equivalent to 500 mg/day—causes numerous signaling pathways inside the heart to be altered,” said Gabriela Rivera, the study’s first author. “These results...
“We found that regular use of acetaminophen at concentrations that are considered safe—equivalent to 500 mg/day—causes numerous signaling pathways inside the heart to be altered,” said Gabriela Rivera, the study’s first author. “These results...
“We found that regular use of...
04/10/2024
Cath Lab Digest
Triglycerides
ACC.24: BRIDGE-TIMI 73a - Study Finds Olezarsen Cuts Triglyceride Levels by About Half
04/10/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“Treatments to reduce high triglycerides are an unmet clinical need,” said Brian Bergmark, MD, the study’s principal investigator. “Based on our study’s results, we can say that the drug worked and appeared to be safe. We tested two doses of...
“Treatments to reduce high triglycerides are an unmet clinical need,” said Brian Bergmark, MD, the study’s principal investigator. “Based on our study’s results, we can say that the drug worked and appeared to be safe. We tested two doses of...
“Treatments to reduce high...
04/10/2024
Cath Lab Digest

Advertisement

Mechanical Circulatory Support
Breakthroughs in Durable Mechanical Circulatory Support (MCS) Devices Aid Heart Failure Patients
04/10/2024

International Society for Heart and Lung Transplantation News

International Society for Heart and L...
“In the next five years, new pumps will have a fully internalized power line and be wirelessly powered from outside the body, just like our iPhones,” said Mandeep R. Mehra, MD, of the Center for Advanced Heart Disease at Brigham Health....
“In the next five years, new pumps will have a fully internalized power line and be wirelessly powered from outside the body, just like our iPhones,” said Mandeep R. Mehra, MD, of the Center for Advanced Heart Disease at Brigham Health....
“In the next five years, new...
04/10/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

News

DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest

Advertisement

Advertisement

TAVR
TAVR UNLOAD @TCT: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis Shows Limited Benefits
10/30/2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD...
10/30/2024
Cath Lab Digest
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use